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Abstract
Introduction. We examined the cost-effectiveness of a rotavirus immunization program in 
Kyrgyzstan, a country eligible for  vaccine funding from  the  GAVI Alliance.
Methods. We estimated the burden of rotavirus disease and its economic consequences by 
using national and international data. A  cost-effectiveness analysis was conducted from 
government and societal perspectives, along with a range of 1-way sensitivity analyses.
Results. Rotavirus-related hospitalizations and outpatient visits cost US$580,864 annually, 
of which $421,658 (73%) is direct medical costs and $159,206 (27%) is nonmedical and 
indirect costs. With 95% coverage, vaccination could  prevent 75%  of  rotavirus-related  
hospitalizations  and deaths and 56% of outpatient visits and could avert
$386,193 (66%) in total costs annually. The medical break-even price at which averted direct 
medical costs equal vaccination  costs  is  $0.65/dose;  the  societal  break-even  price  is  
$1.14/dose  for  a  2-dose  regimen.  At  the  current GAVI  Alliance–subsidized vaccine 
price  of  $0.60/course, rotavirus vaccination is cost-saving for the government.
Vaccination is cost-effective at a vaccine price $9.41/dose, according to the cost-
effectiveness standard set by the 2002 World Health Report.
Conclusions. Addition  of  rotavirus  vaccines  to  childhood  immunization  in  Kyrgyzstan  
could  substantially reduce  disease  burden  and  associated  costs.  Vaccination would be 
cost-effective from the national perspective at a  vaccine price $9.41 per dose
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Rotaviruses are the most common cause of severe di-
arrhea in young children, leading to an estimated
527,000 deaths annually, of which 85% occur in de-
veloping countries [1]. The GAVI Alliance (formerly
known as the Global Alliance for Vaccines and Im-
munization) currently provides 2 new rotavirus vac-
cines at a reduced price to eligible low-income countries
in Europe and Latin America to help advance their
introduction into immunization programs [2]. The de-
cision to commit resources to a given health care in-
tervention should be based on evaluation of costs of
the intervention and its effect on disease; this is per-
formed through cost-effectiveness analyses. Most eco-
nomic evaluations of rotavirus immunization have been
done in industrialized countries [3–6], whereas little
research on the cost-effectiveness of new rotavirus vac-
cines in low-income countries is available [7–9], par-
ticularly GAVI Alliance–eligible countries. Moreover,
the available economic analyses of rotavirus immuni-
zation programs used a wide range of methods, which
makes comparison across countries and regions chal-
lenging [10].
To inform policy makers in resource-limited settings about
the costs and benefits of using rotavirus vaccines, we conducted
a cost-effectiveness analysis of rotavirus vaccination in Uzbek-
istan, a GAVI Alliance–eligible country; this was done before
the GAVI Alliance–subsidized price of the vaccine was known
to the government [11]. Uzbekistan is a member of the Eu-
ropean region of the World Health Organization (WHO),
which covers other countries of the Commonwealth of Inde-
pendent States, including 4 Central Asian countries. The Com-
monwealth of Independent States region is highly diverse, and
economic indicators and levels of morbidity and mortality in
childhood vary substantially among countries, even inside Cen-
tral Asia [12]. Evidence on cost-effectiveness from a single
study, therefore, is insufficient to draw conclusions for other
parts of the region. Recognizing regional diversity and specific
features of GAVI Alliance–eligible countries, we sought to fur-
ther explore the disease costs and benefits of rotavirus im-
munization and selected Kyrgyzstan as a case for this analysis.
By choosing another GAVI Alliance–eligible country, we aimed
to provide data that would be applicable to other GAVI Alli-
ance–eligible countries in the region.
Kyrgyzstan has a gross domestic product of US$490 per cap-
ita [12], and its state-owned health care system provides services
to 5.1 million inhabitants. In addition to the state budget, the
Kyrgyz health care sector receives funds from insurance, private
out-of-pocket payments, and international grants [13, 14]. The
government currently finances only 40% of all vaccines in the
national program [12], but routine childhood vaccinations are
free. Coverage for routine vaccines is high (92%–99%) [15],
with the lowest coverage for vaccination against hepatitis B
virus (90%). On the basis of data from sentinel hospital sur-
veillance for rotavirus, 26% (95% confidence interval [CI],
24%–27%) of all hospitalizations due to diarrhea among chil-
dren aged !5 years in Kyrgyzstan are attributable to rotavirus
(authors’ unpublished data).
The economic analyses presented here aimed to estimate
health care and societal costs of rotavirus disease and to de-
termine whether vaccination would be a good investment with
respect to health care and costs. Analyses were conducted from
the national perspective, when costs incurred only by the gov-
ernment health care sector were considered, and from a broader
societal perspective, when all costs were included.
METHODS
The study was approved by the Kyrgyz National Ethics Com-
mittee and by the Regional Ethics Committee for Medical Re-
search, Oslo, Norway. Study methods were similar to methods
used in the Uzbekistan cost-effectiveness analysis [11], to ensure
comparability of results.
Health care and societal costs. To estimate the economic
burden of rotavirus disease, we combined the numbers of ex-
pected rotavirus-associated events (hospitalizations and out-
patient visits) with the estimates of health care costs for these
events. To estimate costs of rotavirus-related hospitalizations,
we followed WHO guidelines for estimation of the economic
burden of diarrheal disease [16]. We collected data from a
sample of 180 children aged !5 years who were hospitalized
with acute diarrhea in the Republican Hospital of Infectious
Diseases in Bishkek, Kyrgyzstan, and the Children’s Hospital
in Osh, Kyrgyzstan. These hospitals implemented rotavirus sur-
veillance in 2005 and were selected because they represent com-
mon public hospitals that provide inpatient care for children
with diarrhea. No private inpatient facilities are available to
treat patients with infectious diarrhea. Children hospitalized
with diarrhea were enrolled prospectively from 9 February
through 28 April 2008 after written informed consent was ob-
tained from a parent or legal guardian. Costs of treating patients
with any type of diarrhea were assumed to be similar to costs
of treating patients with rotavirus diarrhea.
Data on the use of hospital resources were extracted from
medical charts and included duration of hospitalization, num-
ber and type of diagnostic tests, and quantity of medications
and supplies used during hospitalization. Unit costs of drugs,
diagnostic tests, and bed days were obtained from hospital
records and were combined with data on the use of hospital
resources, to estimate direct medical costs. Children aged !5
years are exempt from copayments for inpatient care, but in-
formal payments to hospital staff remain common. Parents
offer in-kind or cash payments to ensure better care for their
child. These out-of-pocket payments were included in direct
medical costs because our analysis was conducted from societal
and government perspectives. We used the mean duration of
rotavirus-associated hospitalization (5.6 days), which is based
on surveillance data, to ensure that estimates of hospital per
diem costs were applicable to rotavirus gastroenteritis. Costs
of transportation before hospitalization and during the hospital
stay and costs of self-provision of food for caregivers staying
in the hospital together with ill children were combined to
estimate nonmedical costs. Indirect costs were calculated using
the time lost from paid work by all caregivers as a result of the
child’s illness and the monthly household income. We collected
information on nonmedical and indirect costs by interviewing
caregivers with a questionnaire given at hospital discharge.
Costs were collected in local currency and were converted to
US dollars by using the exchange rate for February 2008 [17].
It was not feasible to collect detailed data on costs of out-
patient visits. We therefore used an estimate of the unit cost
of an outpatient visit in Kyrgyzstan based on the Choosing
Interventions that are Cost Effective (CHOICE) estimate pro-
vided by the WHO in 2000 [18]. The CHOICE estimate in
international dollars was first converted to local currency, was
adjusted for inflation [19], and then was converted to 2008 US
dollars [17]. The CHOICE estimate excluded costs of drugs
and diagnostics. These costs were estimated using data on chil-
dren with diarrhea who sought care in outpatient clinics before
hospitalization and whose families covered the costs of drugs
and diagnostics in a form of out-of-pocket expenses. These
costs were added to the CHOICE estimate to derive a total cost
per outpatient visit. Costs of episodes of mild rotavirus disease
among children who received home care and costs of potential
adverse events associated with vaccination were not included.
Model design and vaccination strategy. We used a spread-
sheet model to estimate rotavirus disease burden and associated
costs that would occur with and without vaccination for the
2006 birth cohort ( ) followed up for the first 5n p 116,000
years of life. A full description of the model is available else-
where [9]. Annual numbers of rotavirus deaths, hospitaliza-
tions, and outpatient visits were estimated using hospital
surveillance data, national gastroenteritis statistics, and inter-
national estimates of mortality for children aged !5 years. We
modeled on-time immunization with a 2-dose vaccine at ages
2 months and 4 months and assumed an efficacy against ro-
tavirus hospitalizations and deaths of 85% (95% CI, 69.6%–
93.5%) [20] and an efficacy against outpatient visits of 63%
(range, 56%–70%), on the basis of clinical trails [21] and our
own assumptions. We applied vaccine coverage of 95%, on the
basis of current coverage of diphtheria–tetanus toxoid–pertussis
vaccine [15]. We used vaccine prices of $0.30–$20/course. This
included prices at which rotavirus vaccines are currently avail-
able to Kyrgyzstan from the GAVI Alliance: $0.60/course if
rotavirus vaccine is introduced as a first new vaccine or $0.30/
course if it is introduced as a second new vaccine [2]. Costs
of the vaccination program included the cost of vaccine doses
needed for the birth cohort based on vaccine coverage, 10%
of loss from waste, and $0.50 administration cost per dose;
these costs were based on published estimates [8, 9].
Cost-effectiveness analysis. As a measure of cost-effective-
ness, we computed an incremental cost-effectiveness ratio
(ICER) for all vaccine prices and expressed the ICER as cost
per disability-adjusted life-year (DALY). The DALY loss from
mortality and all symptomatic cases was calculated using pub-
lished methods [11]. The ICER was the net cost of adminis-
tration of rotavirus vaccination minus the medical costs averted
by vaccination, divided by the DALYs or deaths averted by
vaccination. Costs and benefits were discounted to the present
value by using an annual discount rate of 3%. To determine
whether vaccination was cost-effective, we applied the cost-
effectiveness standard of the World Health Report, which sug-
gested that interventions with a cost per DALY less than the
per capita gross domestic product are very cost-effective [22].
To test the robustness of model results, we performed a range
of 1-way sensitivity analyses by varying 1 parameter at a time
and holding all other parameters at their base-case values. Rates
of rotavirus-associated events and estimates of vaccine efficacy,
coverage, price, administration costs, disease costs, and dis-
count rates were varied within 25% or 50% of the base-
case value or with use of ranges from our own data or published
data.
RESULTS
Health care and societal costs. We enrolled 180 children aged
!5 years who were hospitalized with diarrhea. We excluded 5
children because they stayed in the hospital for 114 days (range,
15–20 days); the costs of treating these cases would not be
representative of the costs of treating routine rotavirus cases.
Of 175 recruited children, 93 (53%) were hospitalized in Bish-
kek and 82 (47%) were hospitalized in Osh (Table 1). Of the
175 children, 137 (78%) sought care before hospital admission,
and almost one-half of patients used an outpatient clinic; the
rest sought other points of care. The median distance from the
hospital to a patient’s home was 5 km (range, 1–200 km), and
95% of families used transportation to reach the hospital. Fam-
ilies of children with diarrhea predominantly used savings
(62%) or had to reduce household expenses (31%) to generate
funds to cover the costs associated with illness. The mean cost
of rotavirus-related hospitalization to the government was es-
timated to be $39. The total average cost to society per hos-
pitalized case was calculated to be $87 (range, $25–$666). Med-
ical costs accounted for 52% of the total, and nonmedical and
indirect costs accounted for 48% (Table 2). Of the direct med-
ical costs, 88% were incurred by the health care system, but
households covered 12% of all medical costs by purchasing
additional drugs and by providing informal payments to hos-
pital staff. Indirect costs were $2.50 per child because only 10%
of parents reported losing time from paid work as a result of
the child’s illness.
The unit cost of an outpatient visit, excluding the costs of
drugs and diagnostics, was $2.04, on the basis of CHOICE data
[18]. We assumed that the total cost of a rotavirus-associated
outpatient visit was $8.24 per child, because 47% of surveyed
children with diarrhea sought care at an outpatient clinic before
hospitalization and because their families paid out-of-pocket a
mean of $6.20 for drugs and diagnostics. This value may over-
estimate the costs of treating outpatient diarrhea cases, because
hospitalized cases that were originally outpatient cases are more
severe, but it includes relevant treatment costs and therefore
provides a more comprehensive picture than the unit cost
alone.
Cost-effectiveness analysis. We obtained base-case values
and sensitivity ranges of input parameters to populate the
model, using available data and published research (Table 3).
We estimated that 3895 hospitalizations, 31,160 outpatient vis-
its, and 174 deaths among children aged !5 years (Table 4)
were attributable to rotavirus each year. The total national cost
Table 1. Prehospitalization History of Children Aged !5 Years with Diarrhea and Character-
istics of Households of Patients with Diarrhea in Bishkek and Osh, Kyrgyzstan, 2008
Characteristic
Bishkek
( )n p 93
Osh
( )n p 82
Total
( )n p 175
Type of care before admission
Public outpatient clinic 50 (53.8) 32 (39.0) 82 (46.9)
Pharmacy 9 (9.7) 23 (28.0) 32 (18.3)
Hospital 13 (14.0) 4 (4.9) 17 (9.7)
Private clinic 1 (1.1) 4 (4.9) 5 (2.9)
Traditional healer 0 (0) 1 (1.2) 1 (0.6)
No care 20 (21.5) 18 (22.0) 38 (21.7)
Type of transportation to hospital
Personal car 23 (24.7) 39 (47.6) 62 (35.4)
Ambulance 30 (32.3) 17 (20.7) 47 (26.9)
Taxi 32 (34.4) 10 (12.2) 42 (24.0)
Public transportation 8 (8.6) 8 (9.8) 16 (9.1)
Foot 0 (0) 8 (9.8) 8 (4.6)
Distance to hospital, median km (range) 5 (1–200) 3.5 (1–70) 5 (1–200)
Monthly household income, mean dollars  SD 223  297.6 310  245.1 264  276.9
Children per household, median no. (range) 1 (1–4) 2 (1–8) 2 (1–8)
Adults per household, median no. (range) 2 (1–8) 3 (1–12) 2 (1–12)
Sources of funds
Savings 56 (61.5) 52 (63.4) 108 (61.7)
Reduction in other expenses 29 (31.2) 26 (31.7) 55 (31.4)
Loan from relatives or friends 6 (6.6) 4 (4.9) 10 (5.7)
NOTE. Data are no. (%) of children, unless otherwise indicated. SD, standard deviation.
of rotavirus disease amounts to $580,864/year ($5.01/child/
year), of which $421,658/year (73%), or $3.63/child/year, is
direct medical costs. If vaccine is delivered on schedule, vac-
cination could avert annually 75% of hospitalizations and
deaths and 56% of outpatient visits, resulting in reductions of
63% in direct medical costs and 66% in total costs. If vaccine
is introduced at the current GAVI Alliance–subsidized price of
$0.60/child, the annual cost of the vaccine alone would be
$72,732, and the costs of administration of the immunization
program would be $110,200/year, resulting in a total cost of
$182,932/year. The program cost increases with higher vaccine
prices; at a price of $2/child, the program cost is estimated to
be $352,640, and an expenditure of $85,621 in net medical
costs will be required for vaccination.
The direct medical break-even price at which averted medical
costs equal intervention costs is $0.65/dose for a 2-dose regi-
men. Therefore, introduction of rotavirus vaccines into the
immunization program at current GAVI Alliance–subsidized
prices of $0.30/course and $0.60/course will generate cost sav-
ings from the government perspective (Table 5). Inclusion of
nonmedical and indirect costs results in the societal break-even
price of $1.14/dose. Vaccination could be cost-saving with vac-
cine prices in the range of $1–$2/course from the societal per-
spective. An increase in the vaccine price would require net
financial investment by the government, but the price per vac-
cine dose could be as high as $9.41, and vaccination would still
be cost-effective from the government perspective, according
to the cost-effectiveness standard of the World Health Report
[22].
Sensitivity analyses. The cost-effectiveness of the program
was most sensitive to changes in rates of rotavirus-associated
mortality, estimates of vaccine efficacy against mortality, and
vaccine price (Table 6). For example, decreasing the baseline
mortality of 1.5 deaths per 1000 persons by 25% resulted in
an increase in the ICER of 33%, compared with the base-case
value (218 vs. 290), whereas increasing the mortality by 25%
resulted in a decrease in the ICER by 20%, compared with the
base-case value (218 vs. 174). The cost-effectiveness of the pro-
gram was most sensitive to changes in the vaccine price; prices
of $5/course and $15/course resulted in ICER values of $78/
DALY and $357/DALY, respectively, corresponding to a change
in the ICER of 64%. Varying the vaccine efficacy against mor-
tality had a greater effect on the cost-effectiveness than did
varying the efficacy against hospitalization; adjustment of the
efficacy against mortality to 69.6% increased the ICER by 22%,
compared with the base-case value, whereas 69.6% efficacy
against hospitalization increased the ICER by only 5%. Vari-
ability in rates of rotavirus-associated outpatient visits, hospi-
Table 2. Hospitalization Costs per Case of Diarrhea Incurred by the Health Care
System and Households, Kyrgyzstan, 2008
Cost category
Cost per hospitalized case, 2008 US dollars
Health care
system Household Total (range)
Direct medical
Expenses before hospitalizationa 0 4.6 4.6 (0–123.8)
Diagnostics 4.8 0 4.8 (1.3–13.4)
Drugs 7.8 0.5 8.3 (0–44.2)
Bed daysb 26.4 0 26.4 (23.6–29.2)
Informal paymentsc 0 0.9 0.9 (0–11.0)
Direct nonmedical
Transportation 0 14.5 14.5 (0–236.7)
Self-provision of food 0 24.9 24.9 (0–165.1)
Indirect costs 0 2.5 2.5 (0–43.1)
Total costs 39.0 47.9 86.9 (24.9–666.5)
a Out-of-pocket payments for drugs, diagnostics, and/or consultation fees before hospitalization
for all surveyed patients except for those that sought care at a polyclinic.
b Adjusted for a mean length of hospitalization of 5.6 days for rotavirus-positive patients, as
determined from hospital rotavirus surveillance data.
c Informal payments to hospital care providers who are outside official payment channels.
Table 3. Base-Case Values and Sensitivity Ranges of Input Parameters in the Rotavirus Vaccine
Cost-Effectiveness Model, Kyrgyzstan, 2008
Parameter Base-case value Sensitivity rangea Source(s)
Rotavirus burden, rate per 1000 persons
Mortality 1.5 25% [12], authors’ data
Hospitalization 33.6 25% Authors’ data
Outpatient visit 269 25% Authors’ data
Vaccine efficacy,b %
Against hospitalization and death 85 69.9–93.5 [20]
Against outpatient visit 63 56–70 [21], assumption
Vaccine coverage, % 95 25% and +4% [15]
Hospitalization costs $86.9 25% Authors’ data
Outpatient visit costs $8.2 25% [18], authors’ data
Vaccine price per child $0.60 $0.30–$20 [2], assumption
Administration cost per child $0.50 $0.25–$1.00 [8, 9], assumption
Discount rate, % 3 0–6 [9]
a Percentage of base-case value or 95% confidence interval is used for sensitivity ranges.
b Efficacy of a 2 dose-regimen, under the assumption of on-time administration.
talization and outpatient costs, and vaccine administration costs
had a limited effect on the cost-effectiveness of the program.
Decreasing the vaccine coverage to 71% did not affect the cost-
effectiveness, and using a higher discount rate of 6% resulted
in a change in the ICER of only 1%.
DISCUSSION AND CONCLUSIONS
This study quantified the economic burden of rotavirus disease
and examined the costs and benefits of the addition of new
rotavirus vaccines to routine childhood immunization in a
GAVI Alliance–eligible country inside the European region of
the WHO. The national burden of rotavirus disease in Kyr-
gyzstan results in a total annual cost of US$580,864, of which
$421,658 (73%), or $3.63/child/year, is direct medical costs.
Total health care expenditure of the country in 2004 was es-
timated to be $102 per capita, with the government share con-
stituting 41% and private-out-of-pocket payments accounting
for 51% [14]. Therefore, the medical costs of rotavirus disease
represent 3.5% of total health care expenditure, demonstrating
a substantial economic effect of rotavirus on the health care
Table 4. Estimates of Health and Economic Burden of Rotavirus under the Base-
Case Parameter Values, Kyrgyzstan, 2008
Variable
Without
vaccination
With
vaccination
Averted by
vaccination Decrease, %
No. of rotavirus events
Deaths 174 44 131 75
Hospitalizations 3895 978 2917 75
Outpatient visits 31,160 13,862 17,299 56
Annual costs, $
Medical 421,658 154,630 267,028 63
Nonmedical 149,734 37,659 112,075 75
Indirect 9472 2382 7090 75
Total 580,864 194,671 386,193 66
Table 5. Expected Costs and Benefits of Rotavirus Vaccination
in Kyrgyzstan
Vaccine price,
$/course
Program
cost,a $
Incremental cost-
effectiveness
ratio per DALY, $
Government
perspective
Societal
perspective
0.30 146,566 CS CS
0.60 182,932 CS CS
1.00 231,420 CS CS
2.00 352,640 20 CS
3.00 473,860 48 22
5.00 716,300 104 78
7.00 958,740 160 134
10.00 1,322,400 243 218
NOTE. CS, cost-saving; DALY, disability-adjusted life-year.
a Program cost includes cost of vaccine doses for the national birth cohort
( ) based on vaccine coverage, 10% of vaccine waste, and admin-n p 116,000
istration cost of $0.50 per child.
sector and households. Given the estimates of vaccine efficacy
and vaccine coverage used in the analysis, vaccination could
reduce rotavirus deaths and hospitalizations among children
aged !5 years by 75%, reduce outpatient visits by 56%, and
avert 66% of the total costs.
With the current GAVI Alliance–subsidized vaccine prices of
$0.30–$0.60/course [2], the cost of vaccine needed to immunize
the national birth cohort would be $36,366–$72,732, but an
additional $110,200 is estimated for administration costs. In-
troduction of rotavirus vaccines at current GAVI Alliance–sub-
sidized prices would save costs for the government, because
Kyrgyzstan could receive a “one-off” grant of $100,000 from
the GAVI Alliance to support administration costs of a new
vaccine [2]. Countries will probably pay a higher price for
vaccines in the future because GAVI Alliance funding is tem-
porally limited; moreover, because grants may not fully cover
additional costs of administration of a new vaccine, rotavirus
vaccination may not result in cost savings and will require net
expenditure by the government. However, if the price per vac-
cine dose were as high as $9.41, vaccination would remain cost-
effective from the government perspective.
We could directly compare the results of this study only with
those of our previous cost-effectiveness analysis in Uzbekistan
[11], because of the lack of economic evaluations of rotavirus
disease in GAVI Alliance–eligible countries. If cost estimates
from the study in Uzbekistan are inflated to 2008 US dollars,
the mean cost of rotavirus hospitalization equates to $95 per
child, compared with the estimate of $87 in the present study.
Direct medical and nonmedical costs in Kyrgyzstan contributed
almost equally to the total cost of rotavirus hospitalizations
(52% and 45%, respectively), whereas in Uzbekistan, medical
costs accounted for the largest percentage (89%) of the total
cost, compared with nonmedical costs (10.5%). Indirect costs
in both countries were low because most caregivers were un-
employed women or female siblings, so very few people lost
time from paid work. High nonmedical costs in Kyrgyzstan are
attributed to higher costs of transportation and self-provision
of food for caregivers staying in the hospital with ill children.
If all out-of-pocket payments of Kyrgyz families are considered
together, they account for 54% of the total costs of hospitali-
zations and outpatient visits, thus representing a major source
of financing of health care services for rotavirus cases. These
family-borne costs constitute 30% of the mean monthly house-
hold income, a finding similar to that in Uzbekistan, where
out-of-pocket expenses in 2004 were ∼37% of mean monthly
household income. Savings, reduction in other expenses, and
private loans were used similarly by households in these 2 coun-
tries to cover costs incurred during illness. Because private out-
of-pocket expenses have been shown to considerably reduce
access to health care in Central Asia [13] (particularly for poor
persons), reduction in these costs could be important in re-
ducing inequalities in health care
Our analysis in Uzbekistan [11] demonstrated that rotavirus
vaccination could reduce disease burden by 91% and be cost-
Table 6. Effect of Variability in Key Input Parameters on the Incremental Cost-Effectiveness Ratio
(ICER) of Rotavirus Vaccination, Kyrgyzstan
Input parameter
Parameter
value
Change in
parameter value,a %
ICER per
DALY, $
Change in
ICER,a %
Rotavirus mortality per 1000 persons
Low 1.1 25 290 +33
Base-case 1.5 … 218 …
High 1.9 +25 174 20
Vaccine efficacy against mortality, %
Low 69.6 18 266 +22
Base-case 85.0 … 218 …
High 93.5 +10 198 9
Vaccine price/course, $
Low 5 50 78 64
Base-case 10 … 218 …
High 15 +50 357 +64
Vaccine administration costs per child, $
Low 0.25 50 205 6
Base-case 0.50 … 218 …
High 1.0 +100 243 +11
Hospitalization and outpatient costs, $
Low 65.2 25 233 +7
Base-case 86.9 … 218 …
High 108.6 +25 202 7
NOTE. DALY, disability-adjusted life-year.
a Plus and minus signs indicate percentage increase and decrease in value, respectively, compared with the base-
case value.
effective if the price of vaccine is $25/child, using interna-
tional mortality estimates and under the assumption of a vac-
cine efficacy of 93% against hospitalization and death due to
rotavirus. The similar results for cost-effectiveness are not sur-
prising, because these countries have comparable income levels
and rotavirus disease burden. These findings suggest that ro-
tavirus vaccination in other GAVI Alliance–eligible countries,
particularly in the same region, could also be cost-effective and
perhaps cost-saving, depending on the vaccine price and the
analysis perspective. Economic evaluations are very context spe-
cific, but cost-effectiveness evidence from these 2 studies is
directly comparable and consistent, because we applied the
same methods in both analyses. Our results are in agreement
with other studies done in developing countries that demon-
strated that rotavirus vaccination could be cost-effective if the
vaccine cost is $7.26/dose in Vietnam [8] or $12.96/course
in low-income Asian countries [9].
The strength of our study is the use of consistent methods
to facilitate comparison within the same region and income
strata, but the present study has limitations. Our estimates may
not be precise, because accurate calculation of disease costs is
difficult. We tested the uncertainty of this parameter in the
sensitivity analysis, but the overall economic effect of disease
may have been over- or underestimated. Our cost estimates are
not fully representative, because we calculated the cost of a
hospital bed day on the basis of data from only 2 hospitals;
for outpatient visits, the costs of diagnostics and drugs were
derived from a sample of hospitalized patients with diarrhea
who initially sought outpatient care. This could have been an
overestimate, because it does not reflect costs of treating less
severe outpatient cases that do not result in hospitalization. We
did not include costs of treating nosocomial rotavirus cases or
costs associated with mild episodes of disease among patients
who do not seek health care. Neither did we consider costs of
adverse events associated with rotavirus vaccination, because
available data do not suggest an increased risk of such events
[23]. The risk of possible adverse events and their costs should
be considered in future analyses to obtain a more comprehen-
sive picture of cost-effectiveness, because the safety of these
vaccines in routine immunization has not been demonstrated.
Using a range of epidemiological, clinical, and economic
parameters that are likely to be applicable to many GAVI Al-
liance–eligible countries, our analyses demonstrated that intro-
duction of new rotavirus vaccines in routine childhood im-
munization in Central Asia would greatly reduce the burden
of rotavirus disease and the related health care and societal
costs. Rotavirus immunization at a cost of $9.41 per vaccine
dose would be cost-effective from the national perspective, but
the affordability of the program in the long-term is uncertain,
given that government health care expenditure was ∼$42 per
capita in 2004 [14]. Competing priorities in health care (in-
cluding the need for other vaccines not currently used in the
national immunization program) will dictate resource alloca-
tion and will affect the decision of whether to invest in rotavirus
vaccination.
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